361 related articles for article (PubMed ID: 31995597)
1. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Gouveia M; Jesus G; Inês M; Costa J; Borges M
Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
6. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
Stoecker C; Kim L; Gierke R; Pilishvili T
J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
[TBL] [Abstract][Full Text] [Related]
7. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
Willem L; Blommaert A; Hanquet G; Thiry N; Bilcke J; Theeten H; Verhaegen J; Goossens H; Beutels P
Hum Vaccin Immunother; 2018 May; 14(5):1218-1229. PubMed ID: 29420161
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
Kang DW; Kim CR; Song JY; Park SK
Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
15. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Study of PCV13 Versus PPSV23 in Adults in Chile.
Biagini L; Pezzani M; Rojas R; Fuentealba F
Value Health Reg Issues; 2018 Dec; 17():194-201. PubMed ID: 30447540
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
19. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
20. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.
By A; Sobocki P; Forsgren A; Silfverdal SA
Clin Ther; 2012 Jan; 34(1):177-89. PubMed ID: 22284997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
